Bristol-Myers Squibb faces a major patent cliff with its key product Eliquis, with settled generic entry permitted in the US in 2028 and generic versions already being marketed in some EU countries. This creates significant revenue risk and pressure to bolster the R&D pipeline to offset the expected losses.
Filing excerpt
Under the terms of previously executed settlement agreements, the generic companies with whom BMS settled are permitted to launch in 2028, subject to additional challenges.
What this signalsFilings often name leadership changes, deals and spending plans.
Vendors
Regions named
sec-10kcompetitorNamedGet every 10-K signal for Bristol Myers Squibb and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Bristol Myers Squibb this week?”
The Signal API returns 10-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/7ca57905-d2f4-4588-b6ea-756711d7e746 returns this record as JSON. POST /v1/companies/enrich returns every signal for bms.com.
{
"signal_id": "7ca57905-d2f4-4588-b6ea-756711d7e746",
"signal_type": "sec-10k",
"signal_subtype": "competitorNamed",
"detected_at": "2026-02-17T06:30:02.078+00:00",
"company": {
"name": "Bristol Myers Squibb",
"domain": "bms.com"
},
"data": {
"detail": "Bristol-Myers Squibb faces a major patent cliff with its key product Eliquis, with settled generic entry permitted in the US in 2028 and generic versions already being marketed in some EU countries. This creates significant revenue risk and pressure to bolster the R&D pipeline to offset the expected losses.",
"metrics": {
"timeframe": "multi_year"
},
"summary": "Blockbuster drug Eliquis faces US generic launch in 2028 and active EU competition.",
"excerpts": "Under the terms of previously executed settlement agreements, the generic companies with whom BMS settled are permitted to launch in 2028, subject to additional challenges.",
"relevance": 0.9,
"sentiment": "negative",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/bmy-20251231.htm",
"filing_date": "2026-02-11",
"filing_year": 2026,
"fiscal_year_end": "12/31",
"sales_relevance": "Competitive intelligence",
"signal_category": "market",
"regions_mentioned": [
"U.S.",
"EU"
],
"vendors_mentioned": [
"Pfizer"
]
}
}
curl https://signals.autobound.ai/v1/signals/7ca57905-d2f4-4588-b6ea-756711d7e746 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"bms.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.